Xeris Pharmaceuticals (NSDQ:XERS) said today that it dosed the first patients in a Phase II trial of its ready-to-use liquid glucagon in people with Type 1 diabetes.
The Chicago-based company expects to report top-line data from the study in the second half of 2019.
Get the full story at our sister site, Drug Delivery Business News.